Literature DB >> 11247783

High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin.

J J Saris1, F H Derkx, R J De Bruin, D H Dekkers, J M Lamers, P R Saxena, M A Schalekamp, A H Jan Danser.   

Abstract

Mannose-6-phosphate (man-6-P)/insulin-like growth factor-II (man-6-P/IgF-II) receptors are involved in the activation of recombinant human prorenin by cardiomyocytes. To investigate the kinetics of this process, the nature of activation, the existence of other prorenin receptors, and binding of native prorenin, neonatal rat cardiomyocytes were incubated with recombinant, renal, or amniotic fluid prorenin with or without man-6-P. Intact and activated prorenin were measured in cell lysates with prosegment- and renin-specific antibodies, respectively. The dissociation constant (K(d)) and maximum number of binding sites (B(max)) for prorenin binding to man-6-P/IGF-II receptors were 0.6 +/- 0.1 nM and 3,840 +/- 510 receptors/myocyte, respectively. The capacity for prorenin internalization was greater than 10 times B(max). Levels of internalized intact prorenin decreased rapidly (half-life = 5 +/- 3 min) indicating proteolytic prosegment removal. Prorenin subdivision into man-6-P-free and man-6-P-containing fractions revealed that only the latter was bound. Cells also bound and activated renal but not amniotic fluid prorenin. We concluded that cardiomyocytes display high-affinity binding of renal but not extrarenal prorenin exclusively via man-6-P/IGF-II receptors. Binding precedes internalization and proteolytic activation to renin thereby supporting the concept of cardiac angiotensin formation by renal prorenin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11247783     DOI: 10.1152/ajpheart.2001.280.4.H1706

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  15 in total

1.  Intracrine renin and angiotensin II: a novel role in cardiovascular and renal cellular regulation.

Authors:  Jia L Zhuo
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

Review 2.  Aliskiren: the first direct renin inhibitor for hypertension.

Authors:  Anton H van den Meiracker; A H Jan Danser
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 3.  Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin.

Authors:  Manne Krop; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

Review 4.  Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.

Authors:  Alicia C Reid; Jacqueline A Brazin; Christopher Morrey; Randi B Silver; Roberto Levi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 5.  Is angiotensin II made inside or outside of the cell?

Authors:  Wenxia Chai; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 6.  Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases.

Authors:  Y Wang; R G MacDonald; G Thinakaran; S Kar
Journal:  Mol Neurobiol       Date:  2016-03-19       Impact factor: 5.590

Review 7.  Renin/prorenin-receptor biochemistry and functional significance.

Authors:  Geneviève Nguyen; Céline A Burcklé; Jean-Daniel Sraer
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 8.  Mannose 6-phosphate receptor targeting and its applications in human diseases.

Authors:  M Gary-Bobo; P Nirdé; A Jeanjean; A Morère; M Garcia
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 9.  Cardiovascular effects of losartan and its relevant clinical application.

Authors:  Feichao Xu; Caiping Mao; Yali Hu; Can Rui; Zhice Xu; Lubo Zhang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 10.  The (pro)renin receptors.

Authors:  Geneviève Nguyen; Aurélie Contrepas
Journal:  J Mol Med (Berl)       Date:  2008-03-06       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.